Dermata Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit on Tuesday, October 15, 2024
Dermata Therapeutics, a late-stage biotechnology company focused on skin diseases and conditions, announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , will take place on Tuesday, October 15, 2024.
CEO Gerry Proehl will present at 3:30 PM ET, providing an update on Dermata's Phase 3 acne program followed by a Q&A session. The summit will feature presentations and interactive discussions with CEOs and key management from various healthcare companies, as well as industry panels.
To attend the virtual event, interested parties must sign up for M-Vest membership. Dermata Therapeutics is traded on NASDAQ under the symbols DRMA and DRMAW.
Dermata Therapeutics, una compagnia biotecnologica in fase avanzata focalizzata sulle malattie e condizioni della pelle, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. L'evento, presentato da Maxim Group, si svolgerà martedì 15 ottobre 2024.
Il CEO Gerry Proehl presenterà alle 15:30 ET, fornendo un aggiornamento sul programma di fase 3 per l'acne, seguito da una sessione di domande e risposte. Il summit proporrà presentazioni e discussioni interattive con CEO e management chiave di diverse aziende del settore sanitario, oltre a panel di esperti del settore.
Per partecipare all'evento virtuale, le persone interessate devono registrarsi per la membership M-Vest. Dermata Therapeutics è quotata al NASDAQ con i simboli DRMA e DRMAW.
Dermata Therapeutics, una empresa biotecnológica en una etapa avanzada centrada en enfermedades y condiciones de la piel, anunció su participación en el 2024 Maxim Healthcare Virtual Summit. El evento, presentado por Maxim Group, tendrá lugar el martes 15 de octubre de 2024.
El CEO Gerry Proehl presentará a las 3:30 PM ET, proporcionando una actualización sobre el programa de acné en fase 3, seguido de una sesión de preguntas y respuestas. La cumbre contará con presentaciones y discusiones interactivas con CEOs y gerentes clave de diversas empresas de salud, así como paneles de la industria.
Para asistir al evento virtual, los interesados deben inscribirse para la membresía M-Vest. Dermata Therapeutics se cotiza en NASDAQ bajo los símbolos DRMA y DRMAW.
Dermata Therapeutics는 피부 질환 및 상태에 중점을 두고 있는 후기 단계 생명공학 회사로, 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. 이 행사는 Maxim Group이 주최하며 2024년 10월 15일 화요일에 개최됩니다.
CEO Gerry Proehl는 오후 3:30 ET에 발표하여 Dermata의 3상 여드름 프로그램에 대한 업데이트를 제공하고, 그 후 질의응답 시간이 있을 것입니다. 이번 정상 회담에서는 다양한 의료 회사의 CEO 및 주요 경영진과의 발표 및 상호작용 토론이 진행되며, 업계 패널도 포함될 것입니다.
가상 이벤트에 참석하려면 관심 있는 당사자는 M-Vest 회원 가입을 해야 합니다. Dermata Therapeutics는 NASDAQ에서 DRMA 및 DRMAW 기호로 거래됩니다.
Dermata Therapeutics, une entreprise de biotechnologie en phase avancée axée sur les maladies et conditions de la peau, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. L'événement, présenté par Maxim Group, aura lieu le mardi 15 octobre 2024.
Le PDG Gerry Proehl présentera à 15h30 ET, fournissant une mise à jour sur le programme contre l'acné de phase 3, suivie d'une séance de questions-réponses. Le sommet mettra en avant des présentations et des discussions interactives avec des PDG et des cadres clés de diverses entreprises de santé, ainsi que des panels industriels.
Pour assister à l'événement virtuel, les parties intéressées doivent s'inscrire pour devenir membre de M-Vest. Dermata Therapeutics est cotée au NASDAQ sous les symboles DRMA et DRMAW.
Dermata Therapeutics, ein Biotechnologieunternehmen in der späten Phase mit einem Fokus auf Hautkrankheiten und -zustände, gab seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt. Die Veranstaltung, die von Maxim Group präsentiert wird, findet am Dienstag, den 15. Oktober 2024 statt.
Der CEO Gerry Proehl wird um 15:30 Uhr ET präsentieren und ein Update zum Phase 3 Akneprogramm geben, gefolgt von einer Frage-Antwort-Runde. Der Gipfel wird Präsentationen und interaktive Diskussionen mit CEOs und Schlüsselmanagement von verschiedenen Gesundheitsunternehmen sowie Branchen-Panels umfassen.
Um an der virtuellen Veranstaltung teilzunehmen, müssen sich interessierte Parteien für die M-Vest-Mitgliedschaft anmelden. Dermata Therapeutics wird an der NASDAQ unter den Symbolen DRMA und DRMAW gehandelt.
- None.
- None.
SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced that the Company's CEO, Gerry Proehl, will present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15, 2024, at 3:30PM ET.
Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. They also plan to host several topical industry panels that promise to be timely and engaging. To attend, sign up to become an M-Vest member.
Click here to reserve your seat
Mr. Proehl will provide an update on the Dermata's Phase 3 acne program followed by a Q&A session.
Event: 2024 Maxim Healthcare Virtual Summit
Date: October 15, 2024
Time: 3:30PM (Eastern Time)
Location: Virtual Click here to reserve your seat
About Dermata Therapeutics
Dermata Therapeutics, Inc. is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. The Company's lead product candidate, DMT310, is the Company's first product candidate being developed from its Spongilla technology platform and is currently being evaluated in a Phase 3 program. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: the potential development and commercialization of product candidates; the ability of the Company's product candidates to achieve applicable endpoints in clinical trials; whether the results of the Company's product candidates will lead to future product development; and whether the Company will have the ability to obtain adequate funding for future development of its product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities, and wealth management firm headquartered in New York. Maxim Group provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research, and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board and is a member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit maximgrp.com
Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on accesswire.com
FAQ
When is Dermata Therapeutics (DRMA) presenting at the 2024 Maxim Healthcare Virtual Summit?
What will Dermata Therapeutics (DRMA) discuss during their presentation at the Maxim Healthcare Virtual Summit?
How can I attend the 2024 Maxim Healthcare Virtual Summit where Dermata Therapeutics (DRMA) is presenting?
What is the focus of Dermata Therapeutics (DRMA) as a company?
